MétaCan
Menu
Back to cohort

Anti-angiogenic TKIs in patients with advanced Ewing sarcoma: A systematic review and single-arm meta-analysis.

2024· review· en· W4399629289 on OpenAlexaff
Caio Castro, Ana Paula Belluco, Isabella Michelon, Maria Inez Dacoregio, Jonathan N. Priantti, Maysa Vilbert, Erica C. Koch Hein, Ludimila Cavalcante

Bibliographic record

VenueJournal of Clinical Oncology · 2024
Typereview
Languageen
FieldMedicine
TopicEosinophilic Disorders and Syndromes
Canadian institutionsUniversity of TorontoUniversity Health NetworkPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineSarcomaMeta-analysisEwing's sarcomaOncologyInternal medicinePathology

Abstract

fetched live from OpenAlex

11531 Background: The treatment of patients with localized Ewing Sarcoma (ES) is well established; however, strategies for relapsed disease remain uncertain. Encouraging outcomes have surfaced from early-phase trials assessing tyrosine kinase inhibitors (TKIs) with anti-angiogenic properties in this population. Hence, we conducted a systematic review and meta-analysis to synthesize current data on efficacy and safety of TKIs in patients with ES. Methods: We comprehensively searched PubMed, Embase, and Cochrane databases for clinical trials and cohort studies assessing anti-angiogenic TKIs in the treatment of advanced ES patients who had received at least one previous line of therapy. Main outcomes were objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS), and safety. Heterogeneity was assessed using I 2 statistics. All analyses were conducted using R software (v.4.2.2), employing random effects models. Results: We included 10 studies: four phase II clinical trials and six retrospective cohort studies, comprising 191 patients. The following TKIs were evaluated: cabozantinib, regorafenib, apatinib, anlotinib and sorafenib. Median age in each study varied from 15 to 33 years, and 48.6% of patients had received ≥2 previous lines of therapy. In a pooled analysis of all ES patients treated with TKIs, the ORR was 30.1% (95%IC 16.3-43.8; I 2 =83.14%) and DCR was 66.8% (95%IC 59.4-73.5; I 2 =3.97%). In a comparative analysis stratified by drug, anlotinib was associated with an increased ORR (p<0.01) and no difference was seen in DCR among TKIs assessed (p=0.26). Seven studies evaluated TKIs in monotherapy, while the others included patients treated with TKIs + chemotherapy (CT); TKI+CT displayed higher ORR (p=0.04) and DCR (p=0.05), in a subgroup analysis by treatment strategies. The median PFS varied from 3.5 to 16.0 between drugs, and the overall median PFS was 4.4 months (95%CI 3.4-10). Dose reduction and interruption of treatment due to toxicity were reported in 39.6% and 6% of patients, respectively. Most common grade 3 or 4 adverse events were leukopenia (24.5%), anemia (8.8%), hypertension (5.6%), and diarrhea (4.3%). Conclusions: Anti-angiogenic TKIs are well tolerated and have shown anti-tumoral activity and clinical benefit in the treatment of patients with advanced Ewing sarcoma. Prospective randomized trials with adequate control groups are warranted to further evaluate the benefits of these agents. [Table: see text]

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (broad)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.558
Threshold uncertainty score0.980

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0050.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0340.007
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.235
GPT teacher head0.488
Teacher spread0.253 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicEosinophilic Disorders and SyndromesFrench-language works237,207